ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1484

Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis

Hariprasad Vankayalapati1, Venkatakrishnareddy Yerramreddy1, Philip Bendele2, Alison Bendele3, Rueban Jacob Anicattu Issac4, Ram Sudheer Adluri5, Philip LoGrasso6 and Joel M. Kremer7, 1Early Discovery and Medicinal Chemistry, Arrien Pharmaceuticals, Salt Lake City, UT, 2Principal Investigator CIA models, Bolder BioPATH, Inc., Boulder, CO, 3Pathologist, Bolder BioPATH Inc., Boulder, CO, 4Biology, GVK Biosciences Private Limited., Hyderabad, India, 5GVK Biosciences Private Limited., Hyderabad, India, 6Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, 7Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Janus kinase (JAK), kinase and rheumatoid arthritis (RA), New Therapeutics, Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for developing targeted therapeutics in treating Rheumatoid Arthritis (RA) and other immunological, inflammatory and autoimmune diseases such as systemic lupus erythematosus, psoriasis, psoriatic arthritis, atherosclerosis, ulcerative colitis and crohns disease. Development of selective small-molecule inhibitors for both JAK3 and ITK is challenging due to the highly conserved ATP binding pocket within the Janus and TEC-kinase family members. Three variable amino acids within the ATP binding pocket of JAK3 and ITK were targeted and inhibitors were rationally designed by employing FIELDS platform. The FIELDS assisted in identifying fragments/scaffolds to a series of lead compounds, and SAR efforts lead to the discovery of the first-in-class irreversible dual JAK3 and ITK inhibitor ARN-4079 for the treatment of RA.

Methods: The JAK3 and ITK enzymatic inhibition and selectivity studies were performed at DiscoveRx. The cell-based profiling using SelectScreen was performed at Life Technologies. In vivocytokine and CIA efficacy studies were conducted using BALB/c and DBA/1OlaHsd mouse models.   

Results: Fragment-based discovery and lead optimization of a series of highly selective JAK3 and ITK inhibitors in tandem with control of physicochemical and ADME-Tox properties culminated in selecting clinically ready ARN-4079 from ~300 new chemical entities. ARN-4079 potently inhibited JAK3 and ITK activity with an IC50 = 5 nM, and 33 nM in biochemical kinase assay. The ScanKIENTIC Kds were estimated to be 2.5 and 23 nM. ARN-4079 exhibited over 100-fold cellular selectivity within the JAK family and potently inhibited IL-4 induced STAT6 phosphorylation with an IC50 = 70 nM. Its low mM inhibition in SelectScreen IL-6, IFN-γ, and EPO supported the JAK3 selectivity and inhibition of PLCγ1-mediated calcium release from CD4+T cells (EC50 = 630 nM) via TCR engagement supports its ITK selectivity in cells. In a set of in vivo experiments, ARN-4079 potently inhibited IL-2, IL-4 and IFN-λ production in mice which are the key characteristics supporting its dual activity. Additionally, ARN-4079 was optimized to have many drug like characteristics in terms of solubility, cell permeation, and DMPK properties. ARN-4079 is an orally available entity (%F = 23), demonstrated efficacy 84% at 60 mg/kg which was equivalent to Tofacitinib in the mouse CIA model. PK studies indicated that, after oral dosing of ARN-4079 reached plasma levels (1080 ng/mL) that are higher or comparable to the therapeutic dose of Tofacitinib (627 ng/mL). Moreover, ARN-4079 showed no toxicity up to doses of 300 mg/kg in rats. On the basis of its strong in vivoefficacy and dose tolerability, ARN-4079 was selected for IND enabling studies.

Conclusion: ARN-4079 is a novel, potent, selective small molecule irreversible dual target inhibitor of JAK3 and ITK that has demonstrated dose linear pharmacokinetic, and in vivo efficacy in CIA models on par with Tofacitinib. Safety and IND studies are ongoing to develop ARN-4079 as a therapeutic agent for RA.


Disclosure:

H. Vankayalapati,

Arrien Pharmaceuticals,

4;

V. Yerramreddy,

Arrien Pharmaceuticals ,

1;

P. Bendele,
None;

A. Bendele,
None;

R. J. A. Issac,
None;

R. S. Adluri,
None;

P. LoGrasso,

ArrienPharmaceuticals,

1;

J. M. Kremer,

Arrien Pharmaceuticals,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-of-arn-4079-a-potent-orally-available-dual-target-inhibitor-of-janus-kinase-3-jak3-and-interleukin-2-inducible-t-cell-kinase-itk-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology